Patient reported outcomes in adults with type 2 diabetes on basal insulin randomized to addition of mealtime pramlintide or rapid-acting insulin analogs

What Was Tested

This randomized controlled trial paper looks at Amylin (Islet Amyloid Polypeptide).

To determine whether treatment satisfaction and quality of life were affected by adding mealtime pramlintide or rapid-acting insulin analogs (RAIAs) to basal insulin therapy for patients with inadequately controlled type 2 diabetes.

Why It Was Studied

The sample size was relatively small and there were few non-white subjects.

The schedule for implementation of change in therapy may have affected study outcomes.

Who Took Part

PubMed indexes the participants as adults and middle-aged adults, both men and women.

How the Study Was Run

The design is described as randomized, open-label and multicenter.

Random assignment meant chance, not the researchers, decided who got Amylin (Islet Amyloid Polypeptide) and who got the comparison, which limits bias.

Being open-label, the Amylin (Islet Amyloid Polypeptide) study did not mask who received what.

More than one site took part, so the participants came from several places.

What Was Measured

The schedule for implementation of change in therapy may have affected study outcomes.

The subject headings attached to it are Amyloid, Diabetes Mellitus, Type 2, Hypoglycemic Agents, Insulin, Islet Amyloid Polypeptide, Patient Satisfaction and Quality of Life.

What This Means in Plain Language

The paper is a randomized, open-label and multicenter study of Amylin (Islet Amyloid Polypeptide).

The abstract goes on to report its results in about 10 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2010 (Current medical research and opinion), a journal based in England.

More context: the Amylin (Islet Amyloid Polypeptide) compound page, all human trials.